Ginkgo Cognition Meta-analysis: What the Evidence Says

Quick Answer

Ginkgo Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• After 12 months,therapy was associated with reduced amyloid ß-protein oligomerisation a well as preserved cognition and improved daily functioning. [Feng Jing-Xuan (2026); evidence level 1]
• However, their clinical significance remains uncertain, and certainty of evidence is overall low due to significant heterogeneity. [Feng Jing-Xuan (2026); evidence level 1]
• In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews. [Yang YoungSoon (2026); evidence level 3]
• Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs. [Yang YoungSoon (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For ginkgo cognition meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Feng Jing-Xuan (2026). Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction—meta-analysis of pooled data from randomised clinical trials. DOI: 10.3389/fneur.2025.1658064. PMCID: PMC13023401. PMID: 41908799. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13023401/
• Yang YoungSoon (2026). Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?. DOI: 10.3390/brainsci16040430. PMCID: PMC13114922. PMID: 42041838. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13114922/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.